TriangleHEALTH PROFESSIONAL · SOURCE READING
Dostarlimab
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Microsatellite Instability–High or Mismatch Repair–Deficient Solid Tumors
Indication. Dostarlimab is indicated for adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, whose disease progressed during or after prior treatment and who have no satisfactory alternative treatment options. This indication is not approved in the pediatric population.
Evidence. GARNET (NCT02715284) was a nonrandomized, multicenter, open-label, multicohort trial that evaluated the efficacy of dostarlimab.[10] The expansion cohorts were as follows:[11-14][Level of evidence C3]
Source links and citations
dMMR/MSI-H endometrial cancers.
Mismatch repair–proficient or microsatellite stable endometrial cancers.
Non-small cell lung cancers.
Non-endometrial dMMR/MSI-H and POLE-mutated cancers.
High-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without BRCA variants.
Efficacy. The efficacy population consisted of 209 patients with dMMR recurrent or advanced solid tumors whose disease progressed after systemic therapy and who had no satisfactory alternative treatment options. The objective response rate was 41.6% (95% CI, 34.9%–48.6%), with a 9.1% complete response rate and a 32.5% partial response rate. The median follow-up was 27.7 months.[10]
Source links and citations
Identification of biomarker. The VENTANA MMR RxDx Panel is a companion diagnostic device to select patients with dMMR solid tumors for treatment with dostarlimab.
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice